|Bid||0.0800 x N/A|
|Ask||0.0850 x N/A|
|Day's Range||0.0700 - 0.0950|
|52 Week Range||0.0700 - 0.2400|
|Beta (3Y Monthly)||0.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.38|
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter from SWK related to certain financial covenants for Q3 2019. The nature of the amendment is to set the minimum threshold for Consolidated Unencumbered Liquid Assets required to be maintained by the Company. In connection with the amendment, Acerus agreed to reprice 5,331,563 outstanding common shares purchase warrants currently held by SWK that were issued with the signing of the credit agreement in 2018 (the “Original Warrants”).
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
TORONTO, July 30, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc. (AYTU), which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men's Health experience to capture a significant share of the U.S. market for NATESTO®. Under the terms of the new agreement, Aytu returns the NDA for NATESTO® in the U.S. back to Acerus. Going forward Acerus will assume all regulatory and clinical responsibilities and costs for the product in the U.S. Acerus will take on a more expansive role in matters such as U.S. marketing, reimbursement and medical strategy as part of the companies' joint commercialization committee, and will launch a specialist sales force focused on urologists and endocrinologists (Acerus Sales Channel).
If you own shares in Acerus Pharmaceuticals Corporation (TSE:ASP) then it's worth thinking about how it contributes to...
TORONTO , June 27, 2019 /CNW/ - Acerus Pharmaceuticals Corporation ("Acerus") (ASP.TO) today announced the voting results from its annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario . The six (6) candidates nominated for election to the Acerus board of directors and listed in Acerus' management information circular dated May 15, 2019 , were elected by a majority of the shareholders present in person or represented by proxy at the meeting. Acerus announced today that its shareholders have approved the re‐appointment of PricewaterhouseCoopers LLP as the Auditor of Acerus to hold office until the next annual meeting of shareholders.
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening process for the previously announced New Drug Submission (“NDS”) for avanafil. The dossier is now in active review by Health Canada and Acerus expects review completion and, if approved, Notice of Compliance issuance to be in early Q2 of 2020. Avanafil, a treatment for erectile dysfunction (“ED”), is a new, second generation PDE5 inhibitor, which has increased receptor specificity for fast onset of action and lower off-target side effects.
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it has reached a mutual agreement with Innovus Pharmaceuticals, Inc. (INNV) (“Innovus Pharma”), a California-based specialty pharmaceutical company, to terminate the exclusive distributor and license agreement granting Acerus the rights to commercialize UriVarx® in Canada. “The termination of this license agreement with Innovus is consistent with our renewed strategic focus on prescription products and men’s health,” said Ed Gudaitis, President and Chief Executive Officer of Acerus.
OTCQB:ASPCF) announced today that it has signed a patent license agreement (the “PLA”) with the University of Texas at Austin for technology related to the nasal administration of testosterone. The newly patented, aqueous-based, nasal delivery technology was developed by Robert Josephs, a UT Austin Professor of Clinical and Social Psychology, and Craig Herman, a Doctor of Pharmacy at MedCara Pharmaceuticals in Conrad, Iowa.
OTCQB:ASPCF) announced today its shares have been approved to be quoted on the OTCQB Venture Market and will trade under the symbol “ASPCF” effective immediately. This is the latest development in the Company's strategy to provide improved channels for market participation. "Listing on the OTCQB Venture is part of a long-term strategy to introduce the Company to a broader audience," said Ed Gudaitis, President & CEO of Acerus.
Acerus Pharmaceuticals Corporation will announce its first quarter 2019 financial and operating results on Monday May 13, 2019 before the market opens. The company will host a conference call on Monday, May 13, 2019 at 8:30 a.m.
Acerus Pharmaceuticals Corporation (ASP.TO) (“Acerus” or the “Company”) today announced that it has engaged Paradigm Capital Inc. (“Paradigm”) as its financial advisor to leverage its proprietary nasal delivery technology in cannabinoid applications through licensing, partnership agreements or other transactions with interested parties. On December 11, 2018, Acerus had previously announced the results of its Phase 1 clinical trial (the “trial”) testing a proprietary intranasal formulation of a tetrahydrocannabinol (“THC”)-rich cannabis oil in healthy volunteers.
Acerus Pharmaceuticals Corporation (ASP.TO) announced today that Edward Gudaitis, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference. Mr. Gudaitis’ address will take place at the Metro Toronto Convention Centre, 255 Front Street W, Toronto, Ontario on May 1, 2019 at 10:00 a.m. Eastern Time. The webcast replay will remain available on the company’s website, www.aceruspharma.com for 90 days following the live presentation.
Acerus Pharmaceuticals Corporation (the “Company”) (ASP.TO) is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”) of 23,230,772 common shares of the Company (the “Common Shares”) to directors and management of the Company at a price of $0.195 per Common Share for aggregate proceeds of approximately $4.53 million. The Company intends to use the net proceeds from the Private Placement to fund the Company’s current working capital requirements, including (i) to support its current payment on a royalty buyout for intellectual property related to the Company’s nasal gel technology for Natesto®, (ii) for purposes of deposits to build its inventory in advance of receiving European approval of Natesto® and (iii) ongoing selling, general and administrative expenses and research and development requirements.
Acerus Pharmaceuticals Corporation today reported its financial results for the three and twelve-month period ended December 31, 2018. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards .
Acerus Pharmaceuticals Corporation (ASP.TO) (“Acerus” or the “Company”) today announced that it has filed a New Drug Submission (“NDS”) for Avanafil with Health Canada. Avanafil, a treatment for erectile dysfunction (“ED”), is a new, second generation PDE5 inhibitor, which has increased receptor specificity for fast onset of action and lower off-target side effects. “The filing of the Avanafil NDS is an important next step in solidifying our presence in men’s health.